Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hong Yu
Institution:
Tianjin Medical University General Hospital
Observed institution:
Tianjin Medical University General Hospital
ORCID:
0000-0001-7025-7328
Observed ORCID:
0000-0001-7025-7328
OpenAlex ID:
A5018668124
Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT±MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Lable, Multicenter Clinical Trial
2022
·
Jia Song
, Hui Liu
, et al.
·
Blood
·
7
Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma
2024
·
Miao Chen
, Hong Yu
, et al.
·
Blood
·
1
PDF
A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
2026
·
Runfeng Zhang
, Hong Yu
, et al.
·
British Journal of Haematology
PDF
Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China
2022
·
Zhe Zhuang
, Ying Tian
, et al.
·
Blood
Show more works
View as search
Works count:
4
Citation count:
8
H-index:
1
I10-index:
Year
Topic
Type